Overexpression of Decay Accelerating Factor Mitigates Fibrotic Responses to Lung Injury.


Journal

American journal of respiratory cell and molecular biology
ISSN: 1535-4989
Titre abrégé: Am J Respir Cell Mol Biol
Pays: United States
ID NLM: 8917225

Informations de publication

Date de publication:
Oct 2022
Historique:
pubmed: 28 7 2022
medline: 5 10 2022
entrez: 27 7 2022
Statut: ppublish

Résumé

CD55 or decay accelerating factor (DAF), a ubiquitously expressed glycosylphosphatidylinositol (GPI)-anchored protein, confers a protective threshold against complement dysregulation which is linked to the pathogenesis of idiopathic pulmonary fibrosis (IPF). Since lung fibrosis is associated with downregulation of DAF, we hypothesize that overexpression of DAF in fibrosed lungs will limit fibrotic injury by restraining complement dysregulation. Normal primary human alveolar type II epithelial cells (AECs) exposed to exogenous complement 3a or 5a, and primary AECs purified from IPF lungs demonstrated decreased membrane-bound DAF expression with concurrent increase in the endoplasmic reticulum (ER) stress protein, ATF6. Increased loss of extracellular cleaved DAF fragments was detected in normal human AECs exposed to complement 3a or 5a, and in lungs of IPF patients. C3a-induced ATF6 expression and DAF loss was inhibited using pertussis toxin (an enzymatic inactivator of G-protein coupled receptors), in murine AECs. Treatment with soluble DAF abrogated tunicamycin-induced C3a secretion and ER stress (ATF6 and BiP expression) and restored epithelial cadherin. Bleomycin-injured fibrotic mice subjected to lentiviral overexpression of DAF demonstrated diminished levels of local collagen deposition and complement activation. Further analyses showed diminished release of DAF fragments, as well as reduction in apoptosis (TUNEL and caspase 3/7 activity), and ER stress-related transcripts. Loss-of-function studies using

Identifiants

pubmed: 35895592
doi: 10.1165/rcmb.2021-0463OC
pmc: PMC9564933
doi:

Substances chimiques

CD55 Antigens 0
Cadherins 0
Complement Membrane Attack Complex 0
Glycosylphosphatidylinositols 0
Heat-Shock Proteins 0
RNA, Messenger 0
RNA, Small Interfering 0
Bleomycin 11056-06-7
Tunicamycin 11089-65-9
Complement C3a 80295-42-7
Complement System Proteins 9007-36-7
Pertussis Toxin EC 2.4.2.31
Caspase 3 EC 3.4.22.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

459-470

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL127805
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL109288
Pays : United States
Organisme : NHLBI NIH HHS
ID : HL127805
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL144481
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL094622
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL162171
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL108904
Pays : United States
Organisme : NHLBI NIH HHS
ID : HL118017
Pays : United States
Organisme : NHLBI NIH HHS
ID : HL108904
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL153056
Pays : United States
Organisme : NHLBI NIH HHS
ID : HL153056
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01; HL109288
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118017
Pays : United States
Organisme : NHLBI NIH HHS
ID : HL119682
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL119682
Pays : United States
Organisme : NHLBI NIH HHS
ID : HL094622
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Nat Cell Biol. 2000 Feb;2(2):84-9
pubmed: 10655587
J Exp Med. 2020 Sep 7;217(9):
pubmed: 32717081
Sci Rep. 2018 Dec 18;8(1):17939
pubmed: 30560874
Am J Respir Cell Mol Biol. 2016 Dec;55(6):889-898
pubmed: 27494303
N Engl J Med. 1978 Feb 16;298(7):353-7
pubmed: 146160
J Biol Chem. 1991 Jan 15;266(2):1250-7
pubmed: 1824699
J Clin Invest. 2018 Jan 2;128(1):64-73
pubmed: 29293089
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10562-7
pubmed: 21670280
Am J Respir Cell Mol Biol. 2020 Nov;63(5):601-612
pubmed: 32668192
Sci Rep. 2020 Jul 28;10(1):12620
pubmed: 32724133
Am J Respir Crit Care Med. 2000 Jul;162(1):225-31
pubmed: 10903246
Immunobiology. 2013 Sep;218(9):1131-8
pubmed: 23642836
Microb Pathog. 2020 Dec;149:104586
pubmed: 33091582
Am J Respir Cell Mol Biol. 2020 May;62(5):622-632
pubmed: 31922885
Proc Am Thorac Soc. 2007 Jul;4(3):247-51
pubmed: 17607007
J Clin Invest. 2015 Feb;125(2):521-38
pubmed: 25562319
Hum Gene Ther. 2011 Nov;22(11):1453-60
pubmed: 21568692
J Immunol. 2017 Jun 15;198(12):4837-4845
pubmed: 28500075
Mol Cell. 2000 Dec;6(6):1355-64
pubmed: 11163209
J Immunol. 1988 Oct 1;141(7):2246-52
pubmed: 2459203
J Cell Mol Med. 2015 Nov;19(11):2549-63
pubmed: 26337158
J Immunol. 2013 Oct 15;191(8):4431-9
pubmed: 24043901
J Clin Invest. 2020 Oct 1;130(10):5088-5099
pubmed: 32870817
Mucosal Immunol. 2009 Mar;2(2):103-21
pubmed: 19129758
Exp Eye Res. 2015 Sep;138:126-33
pubmed: 26149093
Am J Pathol. 2012 Jun;180(6):2309-20
pubmed: 22503784
FASEB J. 2014 Oct;28(10):4223-34
pubmed: 24958208
J Biol Chem. 2020 Nov 27;295(48):16393-16410
pubmed: 32967966
J Immunol. 1992 Sep 1;149(5):1736-43
pubmed: 1380537
Mol Immunol. 2009 Sep;46(15):2885-91
pubmed: 19660813
Am J Physiol Lung Cell Mol Physiol. 2018 Mar 1;314(3):L493-L504
pubmed: 29074489
Cell Res. 2010 Jan;20(1):34-50
pubmed: 20010915
Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L1-L10
pubmed: 29565179
J Clin Invest. 2021 Mar 1;131(5):
pubmed: 33465051
Matrix Biol. 2018 Aug;68-69:355-365
pubmed: 29567124
J Biol Chem. 2011 Sep 2;286(35):30972-30980
pubmed: 21757695
Nat Immunol. 2015 Jan;16(1):27-35
pubmed: 25521682
Cell Microbiol. 2019 Oct;21(10):e13085
pubmed: 31290210
Cell Mol Med Open Access. 2017;3(3):
pubmed: 29377033
Am J Respir Crit Care Med. 2010 Feb 1;181(3):254-63
pubmed: 19850947
Mol Genet Metab. 2015 Jan;114(1):62-5
pubmed: 25468649
Annu Rev Immunol. 1989;7:35-58
pubmed: 2469439
Am J Respir Crit Care Med. 1995 Sep;152(3):1087-93
pubmed: 7545058
FASEB J. 2017 Dec;31(12):5543-5556
pubmed: 28821630
J Immunol. 2005 Aug 1;175(3):1894-902
pubmed: 16034133
PLoS One. 2014 Jul 17;9(7):e102860
pubmed: 25032961
J Biol Chem. 2007 Jun 22;282(25):18552-18562
pubmed: 17395591
FASEB J. 2016 Jun;30(6):2336-50
pubmed: 26956419
Respiration. 2013;86(6):441-52
pubmed: 24356558

Auteurs

Ragini Vittal (R)

Division of Pulmonary and Critical Care, Department of Internal Medicine and.

Amanda J Fisher (AJ)

Division of Pulmonary and Critical Care, Department of Medicine and.

Eric L Thompson (EL)

Department of Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana.

Ellyse M Cipolla (EM)

Division of Pulmonary and Critical Care, Department of Internal Medicine and.

Hongmei Gu (H)

Division of Pulmonary and Critical Care, Department of Medicine and.

Elizabeth A Mickler (EA)

Division of Pulmonary and Critical Care, Department of Medicine and.

Ananya Varre (A)

Division of Pulmonary and Critical Care, Department of Internal Medicine and.

Manisha Agarwal (M)

Division of Pulmonary and Critical Care, Department of Internal Medicine and.

Kevin K Kim (KK)

Division of Pulmonary and Critical Care, Department of Internal Medicine and.

Michael R Vasko (MR)

Department of Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana.

Bethany B Moore (BB)

Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan; and.

Vibha N Lama (VN)

Division of Pulmonary and Critical Care, Department of Internal Medicine and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH